PT. RICHMOND, Calif., Aug. 2 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. will host a conference call to discuss its exclusive license and collaboration agreement with Purdue Pharmaceutical Products L.P. to commercialize Intermezzo (zolpidem tartrate sublingual tablet) in the United States. The FDA has established October 30, 2009 as the Prescription Drug User Fee Act (PDUFA) action date for the Intermezzo New Drug Application (NDA).
Conference Call Information Date: Monday, August 3, 2009 Time: 8:30 a.m. ET Dial-in (U.S.): 877-545-1490 Dial-in (International): 719-325-4864
A simultaneous web cast of the conference call will be available on the Investor Relations section of the Transcept website at http://www.transcept.com/. A replay of the call will be available on the website shortly after the conclusion of the call until Monday, September 7, 2009.
A telephone replay of the conference call will be available beginning August 3, 2009 at 11:30 a.m. ET and ending on August 17, 2009. The replay telephone number is 888-203-1112 (U.S.) or 719-457-0820 (International), Replay Passcode: 5541799.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in neuroscience. For further information, please visit the company's website at: http://www.transcept.com/.
Contacts: Transcept Pharmaceuticals, Inc. Greg Mann Director of Corporate Communications (510) 215-3567 gmann@transcept.com The Ruth Group Investors / Media Sara Ephraim Pellegrino / Jason Rando (646) 536-7017 / 7025 spellegrino@theruthgroup.com jrando@theruthgroup.com
Transcept Pharmaceuticals, Inc.
CONTACT: Greg Mann, Director of Corporate Communications, Transcept
Pharmaceuticals, Inc., +1-510-215-3567, gmann@transcept.com; or Investors:
Sara Ephraim Pellegrino, +1-646-536-7017, spellegrino@theruthgroup.com, or
Media: Jason Rando, +1-646-536-7025, jrando@theruthgroup.com, both of The Ruth
Group
Web Site: http://www.transcept.com/
